We wrote a few days ago on the disappointing discontinuation of Pfizer's Exubera, the first inhaled insulin product.
The always-insightful Dr Derek Lowe at In the Pipeline has an excellent commentary on this case, including his own take on the futility of putting lipstick on a pig:
1. Marketing isn't everything. The next time someone tells you about how drug companies can sell junk that people don't need through their powerful, money-laden sales force, spare a thought for Pfizer. The biggest drug company in the world, with the biggest sales force and the biggest cash reserves, couldn't move this turkey. People didn't want it, and they didn't buy it.
- Log in to post comments
More like this
Scott Hensley at the WSJ.com Health Blog had a banner day today with the sad withdrawal by Pfizer of their inhaled insulin product, Exubera. When I was a pharmacy professor in the mid-1990s, we shared Pharma's optimism that an inhaled insulin product would be a godsend for diabetes patients who…
You can't make this stuff up. As PharmaGossip (among others, including the Times) reportst, a drug company pays $2.3 billion in fines to settle charges of unprecedented seriousness about practices that directly put patients at risk, and that came out of a four-year federal investigation. And some…
I know that we have been very fortunate to attract a few new readers over the last year or so. For those, and as a reminder to others, I wanted to focus on some of my major blog influences. One of these is Derek Lowe, an early science blogger who is perhaps the only pharmaceutical company chemist…
I'm sure you've heard of it by now, as numerous blogs (from Big Fat Blog to Effect Measure to Corpus Callosum) have been buzzing with the news of Pfizer's pet obesity drug Slentrol. As a very brief re-cap, this liquid drug is administered to overweight dogs and cats to induce a sense of 'full-ness…
People in the medical, pharmacy, and nursing professions - except those who personally take daily injections - often pooh-pooh and minimize the complaints of patients who dread taking required daily shots, of insulin or any other medication.
Pfizer, and yes, all the other companies who are still working to find other - more patient-friendly - ways to give meds than by injection will continue to do so. That withdrawl is a bump, an expensive one for Pfizer, but one that is often necessary to bring cutting-edge drugs that the public wants, to market .
Hmm, wasn't this the inhalable insulin developed at UM and bought by Pfizer?